Ensifentrine Uses, Dosage, Side Effects and more
Ensifentrine is under investigation in clinical trial NCT04535986 (A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD).
| Attribute | Details |
|---|---|
| Trade Name | Ensifentrine |
| Generic | Ensifentrine |
| Ensifentrine Other Names | Ensifentrine |
| Type | |
| Formula | C26H31N5O4 |
| Weight | Average: 477.565 Monoisotopic: 477.237604498 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Ensifentrine works
Ensifentrine is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4); it is also an activator of the cystic fibrosis transmembrane conductance regulator (CFTR). This drug has bronchodilatory and anti-inflammatory properties due to the dual inhibition; it also has mucous viscosity reduction and improved mucociliary clearance effects due to the CFTR activation. Ensifentrine is currently being investigated against COPD, cystic fibrosis, asthma, other respiratory diseases, and COVID-19.
